Assignee
REATA PHARMACEUTICALS INC
US·44 granted patents·14 pending applications·682 citations·filing 2008–2025
Top patents by PatentIndex Score
58 records- 0198US7915402B2Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ringREATA PHARMACEUTICALS INC·Filed 2009·Granted Mar 29, 2011·105 cites·12 claims
- 0297US10398711B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2018·Granted Sep 3, 2019·15 cites·10 claims
- 0397US9889143B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2016·Granted Feb 13, 2018·19 cites·23 claims
- 0497US9670147B2Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17REATA PHARMACEUTICALS INC·Filed 2015·Granted Jun 6, 2017·21 cites·23 claims
- 0597US9102681B2Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17REATA PHARMACEUTICALS INC·Filed 2013·Granted Aug 11, 2015·31 cites·11 claims
- 0697USRE45325EAntioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ringREATA PHARMACEUTICALS INC·Filed 2013·Granted Jan 6, 2015·35 cites·24 claims
- 0797USRE45288EAntioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ringREATA PHARMACEUTICALS INC·Filed 2013·Granted Dec 9, 2014·34 cites·12 claims
- 0897US7943778B2Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivativesREATA PHARMACEUTICALS INC·Filed 2009·Granted May 17, 2011·89 cites·13 claims
- 0996US11091430B2Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17REATA PHARMACEUTICALS INC·Filed 2020·Granted Aug 17, 2021·4 cites·20 claims
- 1096US10556858B2Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17REATA PHARMACEUTICALS INC·Filed 2018·Granted Feb 11, 2020·13 cites·22 claims
- 1196US9701709B22,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2015·Granted Jul 11, 2017·24 cites·15 claims
- 1296US9512094B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2014·Granted Dec 6, 2016·22 cites·11 claims
- 1396US9090574B2Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ringREATA PHARMACEUTICALS INC·Filed 2013·Granted Jul 28, 2015·30 cites·21 claims
- 1495US10093614B2Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17REATA PHARMACEUTICALS INC·Filed 2017·Granted Oct 9, 2018·14 cites·21 claims
- 1595US9556222B2A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·21 cites·19 claims
- 1695US8993640B22,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Mar 31, 2015·34 cites·23 claims
- 1794US9249089B2Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivativesREATA PHARMACEUTICALS INC·Filed 2013·Granted Feb 2, 2016·30 cites·20 claims
- 1894US9174941B2Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2013·Granted Nov 3, 2015·22 cites·7 claims
- 1993US9884809B2Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·11 cites·11 claims
- 2093US9796668B2Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of useREATA PHARMACEUTICALS INC·Filed 2015·Granted Oct 24, 2017·12 cites·7 claims
- 2193US9757359B2Synthetic triterpenoids and methods of use in the treatment of diseaseREATA PHARMACEUTICALS INC·Filed 2013·Granted Sep 12, 2017·16 cites·25 claims
- 2293US9278912B2C13-hydroxy derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Mar 8, 2016·30 cites·24 claims
- 2392US10501489B2C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2017·Granted Dec 10, 2019·12 cites·15 claims
- 2491US9593074B2C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2013·Granted Mar 14, 2017·17 cites·30 claims
- 2590US10898499B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2019·Granted Jan 26, 2021·2 cites·25 claims
- 2688US11192852B2Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2019·Granted Dec 7, 2021·2 cites·21 claims
- 2787US11406648B2C17-heteroaryl derivatives of oleanolic acid and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·1 cites·19 claims
- 2887US11292781B2Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2017·Granted Apr 5, 2022·4 cites·40 claims
- 2987US11078230B22,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2017·Granted Aug 3, 2021·4 cites·2 claims
- 3087US9155721B2Delayed release, oral dosage compositions that contain amorphous CDDO-MeREATA PHARMACEUTICALS INC·Filed 2014·Granted Oct 13, 2015·4 cites·16 claims
- 3184US11827664B2Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathwayREATA PHARMACEUTICALS INC·Filed 2019·Granted Nov 28, 2023·1 cites·17 claims
- 3283US10717755B2Co-crystal forms of a novobiocin analog and prolineREATA PHARMACEUTICALS INC·Filed 2019·Granted Jul 21, 2020·1 cites·43 claims
- 3382US11814338B2Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·0 cites·37 claims
- 3481US12595278B2Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathwayREATA PHARMACEUTICALS INC·Filed 2023·Granted Apr 7, 2026·0 cites·14 claims
- 3581US11911395B2Methods of treating obesity using antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2018·Granted Feb 27, 2024·1 cites·26 claims
- 3679US2025188053A1Pyrimidine tricyclic enone derivatives for inhibition of ror-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3777US2025059154A1Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewithREATA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3875US2024043465A1Co-crystal forms of a novobiocin analog and prolineREATA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3971US2024360084A1Pyrazole and imidazole compounds for inhibition of il-17 and rorgammaREATA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4070US12545701B2C4-modified oleanolic acid derivatives for inhibition of IL-17 and other usesREATA PHARMACEUTICALS INC·Filed 2023·Granted Feb 10, 2026·0 cites·10 claims
- 4170US12195443B2Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other usesREATA PHARMACEUTICALS INC·Filed 2022·Granted Jan 14, 2025·0 cites·35 claims
- 4269US11059792B2Imidazolyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2016·Granted Jul 13, 2021·1 cites·9 claims
- 4368US11401294B2Co-crystal forms of a novobiocin analog and prolineREATA PHARMACEUTICALS INC·Filed 2020·Granted Aug 2, 2022·0 cites·19 claims
- 4467US2025361263A1C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4567US2015080465A1Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereofREATA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4665US2019091194A1Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereofREATA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4764US12060340B2Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewithREATA PHARMACEUTICALS INC·Filed 2019·Granted Aug 13, 2024·0 cites·20 claims
- 4864US10953020B2Methods of treating Alport syndrome using bardoxolone methyl or analogs thereofREATA PHARMACEUTICALS INC·Filed 2017·Granted Mar 23, 2021·0 cites·24 claims
- 4963US2018265455A1Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulatorsREATA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 5062US12344631B2C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereofREATA PHARMACEUTICALS INC·Filed 2020·Granted Jul 1, 2025·0 cites·9 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →